Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Takeda Pharmaceuticals Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (111)
Cancellation by sponsor (38)
Prescription medicine registration (12)
Australian Public Assessment Report (AusPAR) (10)
Designation or determination (5)
Prescription medicine decision summary (2)
Prescription medicine evaluation (1)

Date

2024 (9)
2023 (7)
2022 (14)
2021 (14)
2020 (13)
2019 (17)
2018 (6)
2017 (34)
2016 (5)
2015 (5)
2014 (14)
2013 (11)
2012 (3)
2010 (1)
2009 (2)
2008 (8)
2007 (2)
2006 (1)
2005 (9)
2002 (1)
2000 (2)
1999 (1)

Results for "[search-keyword]"

Search

Sponsor content

179 result(s) found, displaying 41 to 50

Takeda Pharmaceuticals Australia Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use (329425)

4 February 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use.
KIOVIG (Takeda Pharmaceuticals Australia Pty Ltd)

20 July 2021

Prescription medicine registration

Active ingredients: normal immunoglobulin.
PANTO pantoprazole 20mg (as sodium sesquihydrate) enteric-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

12 July 2021

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
PANTO pantoprazole 20mg (as sodium sesquihydrate) enteric-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

12 July 2021

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
PANTO pantoprazole 40mg (as sodium sesquihydrate) enteric-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

12 July 2021

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
PANTO pantoprazole 40mg (as sodium sesquihydrate) enteric-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

12 July 2021

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
PANTO HEARTBURN RELIEF pantoprazole (as sodium sesquihydrate) 20mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

12 July 2021

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
Notice for mobocertinib (Takeda Pharmaceuticals Australia Pty Ltd)

27 May 2021

Designation or determination

Provisional approval
Takeda Pharmaceuticals Australia Pty Ltd - Electric infusion pump administration set ancelled under Section 41GL(d) of the Act

19 March 2021

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd
Takeda Pharmaceuticals Australia Pty Ltd - Electric infusion pump administration set ancelled under Section 41GL(d) of the Act

19 March 2021

Cancellation by sponsor

Requested by Takeda Pharmaceuticals Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.